This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2009 Oct;32(10):597.

doi: 10.1002/clc.20670.

Spironolactone therapy in heart failure patients with chronic kidney disease

Ricardo Lopes, Patricia Lourenco, Joana Mascarenhas, Ana Azevedo, Paulo Bettencourt

PMID: 19911355
PMCID: PMC6653212
DOI: 10.1002/clc.20670

Comment

Spironolactone therapy in heart failure patients with chronic kidney disease

Ricardo Lopes et al. Clin Cardiol. 2009 Oct.

. 2009 Oct;32(10):597.

doi: 10.1002/clc.20670.

Authors

Ricardo Lopes, Patricia Lourenco, Joana Mascarenhas, Ana Azevedo, Paulo Bettencourt

PMID: 19911355
PMCID: PMC6653212
DOI: 10.1002/clc.20670

No abstract available

PubMed Disclaimer

Comment on

Safety of spironolactone use in ambulatory heart failure patients.
Kandula P, Shah R. Kandula P, et al. Clin Cardiol. 2009 Jun;32(6):347-8. doi: 10.1002/clc.20597. Clin Cardiol. 2009. PMID: 19569078 Free PMC article. No abstract available.

Similar articles

Safety of spironolactone use in ambulatory heart failure patients.
Kandula P, Shah R. Kandula P, et al. Clin Cardiol. 2009 Jun;32(6):347-8. doi: 10.1002/clc.20597. Clin Cardiol. 2009. PMID: 19569078 Free PMC article. No abstract available.
Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency.
Hu Y, Carpenter JP, Cheung AT. Hu Y, et al. Anesth Analg. 2002 Jul;95(1):39-41, table of contents. doi: 10.1097/00000539-200207000-00006. Anesth Analg. 2002. PMID: 12088939
Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators. Vardeny O, et al. Circ Heart Fail. 2014 Jul;7(4):573-9. doi: 10.1161/CIRCHEARTFAILURE.114.001104. Epub 2014 May 8. Circ Heart Fail. 2014. PMID: 24812304 Clinical Trial.
The risks and benefits of aldosterone antagonists.
Sica DA. Sica DA. Curr Heart Fail Rep. 2005 Aug;2(2):65-71. doi: 10.1007/s11897-005-0011-5. Curr Heart Fail Rep. 2005. PMID: 16036053 Review.
Spironolactone in the treatment of congestive heart failure.
Lloyd SJ, Mauro VF. Lloyd SJ, et al. Ann Pharmacother. 2000 Nov;34(11):1336-40. doi: 10.1345/aph.10104. Ann Pharmacother. 2000. PMID: 11098350 Review.

See all similar articles

References

1. Kandula P, Sham R. Safety of spironolactone use in ambulatory heart failure patients. Clin Cardiol 2009; 32(6): 347–348. - PMC - PubMed
1. Lopes RJ, Lourenço AP, Mascarenhas J, Azevedo A, Bettencourt P. Safety of spironolactone use in ambulatory heart failure patients. Clin Cardiol. 2008; 31(11): 509–513. - PMC - PubMed
1. Wencker D. Acute cardio‐renal syndrome: progression from congestive heart failure to congestive kidney failure. Curr Heart Fail Rep 2007; 4(3): 134–138. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information